(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
Live Chart Being Loaded With Signals
Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage women's health in Australia and the United States...
Stats | |
---|---|
Dagens volum | 27 857.00 |
Gjennomsnittsvolum | 32 320.00 |
Markedsverdi | 10.39M |
EPS | $0 ( 2023-08-29 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -15.03 |
ATR14 | $0.0360 (1.60%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2004-08-24 | Patou Gary | Sell | 2 500 | Stock Options |
2004-08-25 | Patou Gary | Sell | 5 500 | Stock Options |
2004-07-01 | Hennessey Robert J | Sell | 1 500 | Stock Options |
2004-06-29 | Kirby Pamela J | Buy | 9 047 | Stock Options(right to buy) |
2004-06-29 | Kirby Pamela J | Buy | 25 000 | Stock Options(right to buy) |
INSIDER POWER |
---|
0.00 |
Last 92 transactions |
Buy: 380 693 | Sell: 1 344 573 |
Volum Korrelasjon
Genetic Technologies Ltd Korrelasjon
10 Mest positive korrelasjoner |
---|
10 Mest negative korrelasjoner |
---|
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Genetic Technologies Ltd Korrelasjon - Valuta/Råvare
Genetic Technologies Ltd Økonomi
Annual | 2023 |
Omsetning: | $8.69M |
Bruttogevinst: | $4.35M (50.09 %) |
EPS: | $-0.120 |
FY | 2023 |
Omsetning: | $8.69M |
Bruttogevinst: | $4.35M (50.09 %) |
EPS: | $-0.120 |
FY | 2022 |
Omsetning: | $6.79M |
Bruttogevinst: | $6.47M (95.27 %) |
EPS: | $-0.0773 |
FY | 2021 |
Omsetning: | $120 554 |
Bruttogevinst: | $-240 473 (-199.47 %) |
EPS: | $-48.00 |
Financial Reports:
No articles found.
Genetic Technologies Ltd
Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include cardiovascular, type 2 diabetes, prostate cancer, and melanoma. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.